Navigation Links
A revolutionary new way of reversing certain cancers

Australian and American scientists have found a way of shrinking tumours in certain cancers a finding that provides hope for new treatments.

The cancers in question are those caused by a new class of genes known as 'microRNAs', produced by parts of the genome that, until recently, were dismissed as 'junk DNA'. While much is still unknown about microRNAs, it is clear that they can interfere with how our genes are 'read'.

The current finding identifies one particular microRNA (microRNA 380) that appears to disable the king of tumour suppressors, the P53 gene. So important is P53, that it is known as the 'guardian of the genome'. In order for a cell to become cancerous, P53 must either be mutated or otherwise disabled.

Dr Alex Swarbrick, from Sydney's Garvan Institute of Medical Research, Dr Susan Woods from Brisbane's Queensland Institute of Medical Research and Dr Andrei Goga from The University of California San Francisco chose to study neuroblastoma, a childhood cancer of the nervous system in which 99% of patients do not have mutations of the P53 gene.

The researchers found instead that neuroblastomas disable p53 by over-producing microRNA 380. When they blocked the microRNA, P53 production resumed, cancer cells died and tumours became much smaller. Their results are reported in the prestigious international journal Nature Medicine, online today.

"The revolutionary thing about this finding is that it's the first time anyone has blocked the growth of a primary tumour by the simple delivery of a microRNA inhibitor," said Swarbrick.

"By that, I mean we delivered the microRNA inhibitor in a way we might give it to a person as a twice-weekly injection not using some genetic trick. It's the closest thing to a clinical result that's yet been published."

"That, of course, makes this microRNA a potential therapeutic target for all cancers that depend on it."

"The other good news is that you don't find this microRNA in normal adult cells. It's very active while we are developing embryos, when cells need to divide very quickly, but after that it appears to get switched off. So by blocking it, you're effectively returning cells to normal."

"We still don't know why it gets switched on again in certain cancers. Apart from neuroblastomas, we often see it in brain tumours and in melanomas that don't have mutations in P53."

So how exactly does it work?

When a gene is transcribed or "read", in this case P53, a copy of the gene is made in RNA. In a normal cell, that P53 RNA carries the instructions to make P53 proteins, which in turn carry out the tumour suppressor function in cells.

"MicroRNAs act to control the production of proteins the molecules that do the work in cells," explained Swarbrick.

"In the cancers we are discussing, our microRNA binds with P53 RNA, preventing it from making proteins. That effectively reduces the number of P53 proteins in a cell and allows the tumour to grow."

"Understanding that certain cancers appear to be regulated like this gives us a new avenue to explore in their treatment."

While this finding is at an early research stage, it holds much promise for the future treatment of early childhood neuroblastomas and other microRNA- induced cancers.


Contact: Alison Heather
Research Australia

Related medicine news :

1. Revolutionary therapy slows tumor growth in advanced breast cancer, Penn research reports
2. Beverly Hills Aesthetics Offers Revolutionary New Celluraze Procedure
3. ELLKAY Introduces Revolutionary Live Insurance Mapping Solution for Diagnostic Laboratories
4. Revolutionary Sports Bottle Unscrews at Both Ends for Easy Cleaning -- Never Deal With Stinky, Moldy Bottles Again
5. Comparing Tuition and Fees Just Got Easier With College Equalizer, the New Revolutionary College Search System Set to Launch Soon
6. Revolutionary scale makes losing weight easier than ever
7. Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success
8. Shakti, Inc. Brings Knee, Back and Foot Comfort with Revolutionary Medical-Based Technology
9. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
10. Good Look Ink Announces Revolutionary Hair Replication Solution
11. Mammoth Selection Announces Revolutionary New Elite Air Purifier
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
Breaking Medicine Technology: